MarketInOut Stock Screener Log In | Sign Up

Acurx Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/18/2026 16:00
Acurx Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5.94 mln
Float5.11 mln
Earnings Date03/18/2027

Piotroski F-Score

4 / 9
Borderline

1-Year Forecast

10.33
Transformational upside

Relative Strength

61 / 100
Outperforming

ROE

-129
Deeply negative

ROA

-90.66
Deeply negative

Business Description

Acurx Pharmaceuticals is a New York-based drug development company focused on creating new antibiotics to fight serious bacterial infections. Its furthest-along drug, ibezapolstat, works differently from existing antibiotics by blocking a specific bacterial enzyme, and is currently being tested in mid-stage clinical trials for a dangerous gut infection called C. difficile. The company is also working on a second treatment, ACX-375C, designed to combat several hard-to-treat bacteria, including MRSA and other strains that have developed resistance to common antibiotics.

Key Fundamentals

EPS-2.67
ROE-129
ROIC-9,322
ROA-90.66
EBITDA, mln-8.10
EV / EBITDA0.53
EV / EBIT0.53

Quote Details

Last 1.00
Change 0.01 (1.01%)
Open 1.03
Volume 76,858
Turnover 76,858
Average Volume 106,468

Financial Ratios

Leverage Ratio1.41
Current Ratio3.45
Price / Book0.69
Price / Tangible Book0.70

Financial Strength

Piotroski F-Score 4 / 9
1-Year Target Price10.33
Short Ratio1.35
Short % of Float1.83

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.91% 58 / 100   
1 Month -12.28% 30 / 100   
2 Months -32.43% 22 / 100   
6 Months -47.09% 17 / 100   
1 Year -76.3% 10 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog